PeptiCRAd-1 for treatment of melanoma, triple-negative breast cancer or non-small cell lung cancer.
The clinical trial "VALO-001" is open for recruitment in Germany
PeptiCRAd-1 (Peptide-coated Conditionally Replicating Adenovirus 1) in combination with immune checkpoint inhibitor (CPI), pembrolizumab in patients with melanoma, triple-negative breast cancer or non-small cell lung cancer
IF YOU ARE INTERETSED TO PARTICIPATE AS A STUDY PATIENT
Krankenhaus Nordwest, Klinik für Hämatologie und Onkologie, Steinbacher Hohl 2-26, 60488 Frankfurt am Main
Tel.: 069 / 7601 1
Nationales Centrum für Tumorerkrankungen (NCT) Heidelberg, Im Neuenheimer Feld 460, 69120 Heidelberg
Tel.: 06221/ 56 5615
The study physician will evaluate if you may be a suitable candidate for the study. For example, participants must have a certain stage of disease, health status, and be eligible for treatment with pembrolizumab in order to be included in the study. The physician at the study site can evaluate your eligibility based on the inclusion and exclusion criteria for the study.
Clinical trial registry: https://www.clinicaltrials.gov/ct2/show/NCT05492682